Listed

Henry Schein Inc: Form 10-Q for the period ended Sep 30, 2023

Filed with the SEC on Nov 28, 2023 and accepted by EDGAR at Nov 28, 2023, 16:01 ET.

Share

Management's discussion and analysis

As filed, 53,447 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we

provide the following cautionary remarks regarding important factors that, among others, could cause future results

to differ materially from the forward-looking statements, expectations and assumptions expressed or implied

herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of

future performance. These forward-looking statements involve known and unknown risks, uncertainties and other

factors that may cause our actual results, performance and achievements or industry results to be materially

different from any future results, performance or achievements expressed or implied by such forward-looking

statements. These statements are generally identified by the use of such terms as “may,” “could,” “expect,”

“intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable

terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in

the documents we file with the Securities and Exchange Commission (SEC), including our Annual Report on Form

10-K. Forward looking statements include the overall impact of the Coronavirus Disease 2019 (COVID-19) on us,

our results of operations, liquidity and financial condition (including any estimates of the impact on these items),

the rate and consistency with which dental and other practices resume or maintain normal operations in the United

States and internationally, expectations regarding PPE products and COVID-19 related product sales and inventory

levels, whether additional resurgences or variants of the virus will adversely impact the resumption of normal

operations, whether supply chain disruptions will adversely impact our business, the impact of the cybersecurity

incident disclosed in the Company’s Current Report on Form 8-K filed on October 15, 2023 on our business and

results of operations, including the accuracy of our estimates of the impact, the timing and extent of any recovery

on insurance claims, the impact of integration and restructuring programs as well as of any future acquisitions,

general economic conditions including exchange rates, inflation and recession, and more generally current

expectations regarding performance in current and future periods. Forward looking statements also include (i) our

ability to have continued access to a variety of COVID-19 test types, and COVID-19 vaccines and ancillary

supplies, and (ii) expectations regarding COVID-19 test sales, demand and inventory levels.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results

include, but are not limited to: risks associated with COVID-19 and any variants thereof, as well as other disease

outbreaks, epidemics, pandemics, or similar wide-spread public health concerns and other natural disasters; our

dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and

maintain and protect new products (particularly technology products) and technologies that achieve market

acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint

ventures, including the failure to achieve anticipated synergies/benefits; legal, regulatory, compliance,

cybersecurity, financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions

in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates

or other purchasing incentives; risks related to the sale of corporate brand products; effects of a highly competitive

(including, without limitation, competition from third-party online commerce sites) and consolidating market; the

repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry;

risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs

for our products or other service issues with our third-party shippers; general global and domestic macro-economic

and political conditions, including inflation, deflation, recession, fluctuations in energy pricing and the value of the

U.S. dollar as compared to foreign currencies, and changes to other economic indicators, international trade

agreements, potential trade barriers and terrorism; geopolitical wars; failure to comply with existing and future

regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and

regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations

relating to the collection, storage and processing of sensitive personal information or standards in electronic health

records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other

claims; litigation risks; new or unanticipated litigation developments and the status of litigation matters; risks

associated with customs policies or legislative import restrictions; cyberattacks or other privacy or data security

breaches (including the recent October 2023 incident); risks associated with our global operations; our dependence

on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control

or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction

of actual results. We undertake no duty and have no obligation to update forward-looking statements except as

required by law.

Where You Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public

conference calls and webcasts, press releases, the investor relations page of our website (www.henryschein.com (http://www.henryschein.com))

and the social media channels identified on the Newsroom page of our website.

Recent Developments

During the year ended December 31, 2022 we experienced a decrease in the sales of PPE and COVID-19 test kits

as compared to the comparable prior-year period. During the three and nine months ended September 30, 2023, we

continued to experience a decrease in the sales of PPE and COVID-19 test kits, primarily due to ongoing decreases

in market prices for PPE (principally gloves) and lower market demand for COVID-19 test kits compared with the

same periods in the prior year, and we expect further decreases in sales in 2023 compared to the prior year.

While the U.S. economy has recently experienced inflationary pressures and strengthening of the U.S. dollar, their

impacts have not been material to our results of operations. The impact from inflation, including manufacturer

price increases excluding PPE products, was slightly more pronounced in Europe. Though inflation impacts both

our revenues and costs, the depth and breadth of our product portfolio often allows us to offer lower-cost national

brand solutions or corporate brand alternatives to our more price-sensitive customers who are unable to absorb

price increases, thus positioning us to protect our gross profit.

Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among

other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity

investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income

tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of

compensation cost for certain share-based performance awards and cash bonus plans; and pension plan

assumptions.

Cybersecurity Incident

On October 14, 2023, we became aware of a cybersecurity incident that primarily affected the operations of our

North American and European dental and medical distribution businesses. Henry Schein One, our practice

management software, revenue cycle management and patient relationship management solutions business was not

affected, and our manufacturing businesses and our equipment sales and service operations were mostly unaffected.

Once we became aware of the issue, we took steps to assess, contain and remediate this incident. Our distribution

operations resumed and we reactivated our ecommerce platform. We also notified law enforcement and our

customers and suppliers informing them of both the incident and management’s efforts to mitigate its impact on our

daily operations. As previously disclosed, while our forensic investigation is still ongoing, we have determined that

a data breach occurred. We are notifying potentially affected parties as appropriate.

On November 22, 2023, we experienced a disruption to our ecommerce platform and related applications. The

Company has restored its ecommerce platform and certain other applications in the United States, Canada and

certain European countries. Our ecommerce platform in the remaining European countries and other applications

are expected to follow shortly.

We continue to review the impact of the incident on our business. As previously disclosed, we believe the incident

will adversely impact our financial results for the fourth quarter and full year 2023.

We maintain cyber insurance, subject to certain retentions and policy limitations. There can be no assurance that

the insurance coverage we maintain is sufficient to cover costs and expenses related to this cybersecurity incident.

Executive-Level Overview

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and

technology.

We

believe we are the world’s largest provider of health care products and services primarily to office-

based dental and medical practitioners, as well as alternate sites of care.

We

serve more than one million customers

worldwide including dental practitioners, laboratories, physician practices, and ambulatory surgery centers, as well

as government, institutional health care clinics and other alternate care clinics.

We

believe that we have a strong

brand identity due to our more than 91 years of experience distributing health care products.

We are headquartered in Melville, New York, employ approximately 24,000 people (of which approximately

11,500 are based outside of the United States) and have operations or affiliates in 33 countries and territories. Our

broad global footprint has evolved over time through our organic success as well as through contribution from

strategic acquisitions.

We

have established strategically located distribution centers around the world to enable us to better serve our

customers and increase our operating efficiency. This infrastructure, together with broad product and service

offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of

supply for our customers’ needs.

While our primary go-to-market strategy is in our capacity as a distributor, we also market and sell our own

corporate brand portfolio of cost-effective, high-quality consumable merchandise products, manufacture certain

dental specialty products in the areas of implants, orthodontics and endodontics, and repackage/relabel prescription

drugs and/or devices.

We

have achieved scale in these global businesses primarily through acquisitions, as

manufacturers of these products typically do not utilize a distribution channel to serve customers.

We

conduct our business through two reportable segments: (i) health care distribution and (ii) technology and

value-added services. These segments offer different products and services to the same customer base. Our global

dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other

institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency

medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as

group practices and integrated delivery networks, among other providers across a wide range of specialties.

The health care distribution reportable segment, combining our global dental and medical operating segments,

distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services,

branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant,

orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins.

Our global technology and value-added services business provides software, technology and other value-added

services to health care practitioners. Our technology business offerings include practice management software

systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy,

education, revenue cycle management and financial services on a non-recourse basis, e-services, practice

technology, network and hardware services, as well as consulting, and continuing education services for

practitioners.

A key element to grow closer to our customers is our One Schein initiative, which is a unified go-to-market

approach that enables practitioners to work synergistically with our supply chain, equipment sales and service and

other value-added services, allowing our customers to leverage the combined value that we offer through a single

program. Specifically, One Schein provides customers with streamlined access to our comprehensive offering of national brand products, our corporate brand products and proprietary specialty products and solutions (including implant, orthodontic and endodontic products). In addition, customers have access to a wide range of services, including software and other value-added services.

Industry Overview

In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited

distributors capable of providing a broad array of products and services at low prices. It also has accelerated the

growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to

their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing

specialized management information support.

We

believe that the trend towards cost containment has the potential

to favorably affect demand for technology solutions, including software, which can enhance the efficiency and

facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we

undertook to expand our business, domestically and internationally, in part to address significant changes in the

health care industry, including consolidation of health care distribution companies, health care reform, trends

toward managed care, cuts in Medicare and collective purchasing arrangements.

Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented

and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices

or service organizations ranging in size from a few practitioners to a large number of practitioners who have

combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies

in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners

has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete

order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the

practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than

one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to

partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician

hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or

professional staff level; however, orders are delivered to the practitioners’ offices.

We

believe that consolidation within the industry will continue to result in a number of distributors, particularly

those with limited financial, operating and marketing resources, seeking to combine with larger companies that can

provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire

companies that can enhance their current product and service offerings or provide opportunities to serve a broader

customer base.

Our approach to acquisitions and joint ventures has been to expand our role as a provider of products and services

to the health care industry. This trend has resulted in our expansion into service areas that complement our existing

operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we

have the ability to support increased sales through our existing infrastructure, although there can be no assurances

that we will be able to successfully accomplish this.

We

also have invested in expanding our sales/marketing

infrastructure to include a focus on building relationships with decision makers who do not reside in the office-

based practitioner setting.

As the health care industry continues to change, we continually evaluate possible candidates for joint venture or

acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to

the health care industry. There can be no assurance that we will be able to successfully pursue any such

opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or

consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the

integration efforts associated with any such transaction would be successful.

Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth due to the aging population,

increased health care awareness, the proliferation of medical technology and testing, new pharmacological

treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment on

insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and

diagnostic testing from acute care settings to alternate-care sites, particularly physicians’ offices.

According to the U.S. Census Bureau’s International Database, between 2023 and 2033, the 45 and older

population is expected to grow by approximately 11%. Between 2023 and 2043, this age group is expected to grow

by approximately 21%. This compares with expected total U.S. population growth rates of approximately 6%

between 2023 and 2033 and approximately 11% between 2023 and 2043.

According to the U.S. Census Bureau’s International Database, in 2023 there are approximately seven million

Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care

services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population

aged 65 to 84 years is projected to increase by approximately 23% during the same period.

As a result of these market dynamics, annual expenditures for health care services continue to increase in the

United States. We believe that demand for our products and services will grow while continuing to be impacted by

current and future operating, economic, and industry conditions. The Centers for Medicare and Medicaid Services,

or CMS, published “National Health Expenditure Data” indicating that total national health care spending reached

approximately $4.3 trillion in 2021, or 18.3% of the nation’s gross domestic product, the benchmark measure for

annual production of goods and services in the United States. Health care spending is projected to reach

approximately $7.2 trillion by 2031, or 19.6% of the nation’s projected gross domestic product.

Government

Certain of our businesses involve the distribution, manufacturing, importation, exportation, marketing and sale of,

and/or third party payment for, pharmaceuticals and/or medical devices, and in this regard, we are subject to

extensive local, state, federal and foreign governmental laws and regulations, including as applicable to our

wholesale distribution of pharmaceuticals and medical devices, manufacturing activities, and as part of our

specialty home medical supply business that distributes and sells medical equipment and supplies directly to

patients. Federal, state and certain foreign governments have also increased enforcement activity in the health care

sector, particularly in areas of fraud and abuse, anti-bribery and corruption, controlled substances handling, medical

device regulations and data privacy and security standards.

Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations,

including with respect to the sale, transportation, importation, storage, handling and disposal of hazardous or

potentially hazardous substances; “forever chemicals” such as per-and polyfluoroalkyl substances (PFAS); and safe

working conditions. In addition, certain of our businesses must operate in compliance with a variety of burdensome

and complex coding, billing and record-keeping requirements in order to substantiate claims for payment under

federal, state and commercial healthcare reimbursement programs. One of these businesses was suspended in

October 2021 by CMS from receiving payments from Medicare, although it was permitted to continue to perform

and bill for Medicare services. Such suspension was terminated on September 30, 2022.

Government and private insurance programs fund a large portion of the total cost of medical care, and there have

been efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010. In addition, activities to control medical costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices, medical supplies, and/or medical treatments or services, are ongoing. Many of these laws and regulations are subject to change and their evolving implementation may impact our operations and our financial performance.

Our businesses are generally subject to numerous laws and regulations that could impact our financial performance,

and failure to comply with such laws or regulations could have a material adverse effect on our business.

A more detailed discussion of governmental laws and regulations is included in Management’s Discussion &

Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K for the

fiscal year ended December 31, 2022, filed with the SEC on February 21, 2023.

Results of Operations

The following tables summarize the significant components of our operating results for the three and nine months

ended September 30, 2023 and September 24, 2022 and cash flows for the nine months ended September 30, 2023

and September 24, 2022:

Three Months Ended

Nine Months Ended

September 30,

September 24,

September 30,

September 24,

2023

2022

2023

2022

Operating results:

Net sales

3,162

3,067

9,322

9,276

Cost of sales

2,167

2,153

6,386

6,444

Gross profit

995

914

2,936

2,832

Operating expenses:

Selling, general and administrative

725

648

2,149

2,010

Depreciation and amortization

59

45

152

137

Restructuring and integration costs

11

10

59

10

Operating income

200

211

576

675

Other expense, net

(21)

(6)

(48)

(17)

Net income

143

162

419

515

Net income attributable to Henry Schein, Inc.

137

150

398

491

Nine Months Ended

September 30,

September 24,

2023

2022

Cash flows:

Net cash provided by operating activities

532

348

Net cash used in investing activities

(808)

(211)

Net cash provided by (used in) financing activities

(121)

Plan of Restructuring and Integration Costs

On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and

streamlining operations and other initiatives to increase efficiency. We revised our previous expectations of

completion and now expect this initiative to extend through 2024. We are currently unable in good faith to make a

determination of an estimate of the amount or range of amounts expected to be incurred in connection with these

activities, both with respect to each major type of cost associated therewith and with respect to the total cost, or an

estimate of the amount or range of amounts that will result in future cash expenditures.

During the three months ended September 30, 2023 and September 24, 2022, we recorded restructuring costs of

$11 million and $9 million, respectively. During the nine months ended September 30, 2023 and September 24,

2022, we recorded restructuring costs of $59 million and $9 million, respectively. The restructuring costs for these

periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease

assets and fixed assets, and other lease exit costs. Included in restructuring costs for the nine months ended

September 30, 2023 were immaterial amounts related to the disposal of an unprofitable U.S. business initiated

during 2022 and completed during the first quarter of 2023.

On August 26, 2022, we acquired Midway Dental Supply. In connection with this acquisition, during the three

months ended September 24, 2022, we recorded integration costs of $1 million related to one-time employee and

other costs, as well as restructuring charges of $2 million, which are included in the $9 million of restructuring

charges discussed above.

Three Months Ended September 30, 2023 Compared to Three Months Ended September 24, 2022

Net Sales

Net sales were as follows:

September 30,

% of

September 24,

% of

Increase / (Decrease)

2023

Total

2022

Total

Health care distribution

(1)

Dental

1,882

59.5

1,785

58.2

97

5.4

Medical

1,070

33.9

1,106

36.0

(36)

(3.1)

Total health care distribution

2,952

93.4

2,891

94.2

61

2.1

Technology and value-added services

(2)

210

6.6

176

5.8

34

18.8

Total

3,162

100.0

3,067

100.0

95

3.1

The components of our sales growth were as follows:

Total Local

Currency

Growth

Foreign

Exchange

Impact

Total Sales

Growth

Local Currency Growth

Local Internal

Growth

Acquisition

Growth

Health care distribution

(1)

Dental Merchandise

0.3

4.8

5.1

1.8

6.9

Dental Equipment

(2.0)

0.9

(1.1)

1.7

0.6

Total Dental

(0.2)

3.8

3.6

1.8

5.4

Medical

(4.6)

1.4

(3.2)

0.1

(3.1)

Total Health Care Distribution

(1.9)

2.9

1.0

1.1

2.1

Technology and value-added services

(2)

9.6

8.6

18.2

0.6

18.8

Total

(1.2)

3.2

2.0

1.1

3.1

Note: Percentages for Net Sales; Gross Profit; Selling, General and Administrative; Other Expense, Net; and Income Taxes are based on

actual values and may not recalculate due to rounding.

(1)

Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and

generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic

products), diagnostic tests, infection-control products, PPE products and vitamins.

(2)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,

practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing

education services for practitioners, consulting and other services.

Global Sales

Global net sales for the three months ended September 30, 2023 increased 3.1% and was primarily attributable to

acquisitions. The components of our sales growth are presented in the table above.

The estimated increase in internally generated local currency sales, excluding PPE products and COVID-19 test

kits, was 1.1%. We estimate that sales of PPE products and COVID-19 test kits were approximately $175 million

and $244 million for the three months ended September 30, 2023 and September 24, 2022, respectively,

representing an estimated decrease of $69 million or 28.2% versus the prior year, with the $69 million net decrease

year-over-year representing 2.2% of global net sales for the three months ended September 30, 2023.

Dental

Dental net sales for the three months ended September 30, 2023 increased 5.4%. The components of our sales

growth are presented in the table above. Our sales growth in local currency for dental merchandise was 5.1% and

was primarily attributable to acquisitions. Our decrease in sales in local currency for dental equipment was

primarily attributable to a slowdown in digital equipment sales, partially offset by growth in North America for

traditional dental equipment.

The estimated increase in internally generated local currency sales, excluding PPE products, was 0.3%. We

estimate that sales of PPE products were approximately $83 million and $94 million for the three months ended

September 30, 2023 and September 24, 2022, respectively, representing an estimated decrease of $10 million or

11.0% versus the prior year, with the $10 million net decrease year-over-year representing 0.5% of dental net sales

for the three months ended September 30, 2023.

Medical

Medical net sales for the three months ended September 30, 2023 decreased 3.1%. The components of this

decrease are presented in the table above. The local currency decrease in medical sales is primarily attributable to

lower sales of PPE products and COVID-19 test kits.

The estimated increase in internally generated local currency sales, excluding PPE products and COVID-19 test

kits, was 0.8% and was adversely impacted by a replacement of branded pharmaceutical sales with lower priced

generic products and an increase in lower priced corporate brand sales. We estimate that sales of PPE products and

COVID-19 test kits were approximately $92 million and $150 million for the three months ended September 30,

2023 and September 24, 2022, respectively, representing an estimated decrease of $59 million or 39.0% versus the

prior year, with the $59 million net decrease year-over-year representing 5.4% of medical net sales for the three

months ended September 30, 2023.

Technology and value-added services

Technology and value-added services net sales for the three months ended September 30, 2023 increased 18.8%

driven by acquisitions and revenue of practice management solutions. The components of our sales growth are

presented in the table above. During the three months ended September 30, 2023, the trend for sales of practice

management software growth remains strong as we continued to increase the number of cloud-based users.

Gross Profit

Gross profit and gross margin percentages by segment and in total were as follows:

September 30,

Gross

September 24,

Gross

Increase

2023

Margin %

2022

Margin %

Health care distribution

851

28.8

799

27.7

52

6.5

Technology and value-added services

144

68.7

115

65.0

29

25.5

Total

995

31.5

914

29.8

81

8.8

As a result of different practices of categorizing costs associated with distribution networks throughout our

industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we

realize substantially higher gross margin percentages in our technology and value-added services segment than in

our health care distribution segment. These higher gross margins result from being both the developer and seller of

software products and services, as well as certain financial services. The software industry typically realizes higher

gross margins to recover investments in research and development.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in

the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting

our gross profit margin. For example, sales of our corporate brand products achieve gross profit margins that are

higher than average total gross profit margins of all products. With respect to customer mix, sales to our large-

group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the

gross margin on sales to office-based practitioners, who normally purchase lower volumes.

Health care distribution gross profit increased primarily due to the increase in net sales discussed above, including

$35 million of gross profit from acquisitions and gross margin expansion, mainly as a result of a favorable impact

of sales mix of higher-margin products.

Technology and value-added services gross profit increased as a result of a higher gross profit from internally

generated sales and gross profit of $13 million from acquisitions, as well as an increase in gross margin rates,

primarily due to product mix.

Operating Expenses

Operating expenses (consisting of selling, general and administrative expenses; depreciation and amortization; and

restructuring and integration costs) by segment and in total were as follows:

% of

% of

September 30,

Respective

September 24,

Respective

Increase

2023

Net Sales

2022

Net Sales

Health care distribution

691

23.4

620

21.5

71

11.3

Technology and value-added services

104

49.7

83

47.2

21

25.1

Total

795

25.1

703

22.9

92

12.9

The net increase in operating expenses is attributable to the following:

Restructuring and

Integration Costs

Operating Costs

Acquisitions

Total

Health care distribution

65

6

71

Technology and value-added services

1

(8)

28

21

Total

1

57

34

92

The restructuring and integration costs are primarily related to severance and employee-related costs, and other

lease exit costs. The increase in operating costs includes increases in payroll and payroll related costs, facility

related costs and consulting expenses in both of our reportable segments, and increased acquisition expenses in our

healthcare distribution segment.

Other Expense, Net

Other expense, net was as follows:

September 30,

September 24,

Variance

2023

2022

Interest income

6

1

5

300.2

Interest expense

(25)

(8)

(17)

(202.6)

Other, net

(2)

1

(3)

(292.4)

Other expense, net

(21)

(6)

(15)

(252.2)

Interest income increased primarily due to increased interest rates. Interest expense increased primarily due to

increased borrowings and increased interest rates.

Income Taxes

For the three months ended September 30, 2023 our effective tax rate was 21.9% compared to 22.7% for the prior

year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state

and foreign income taxes and interest expense.

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 24, 2022

Net Sales

Net sales were as follows:

September 30,

% of

September 24,

% of

Increase / (Decrease)

2023

Total

2022

Total

Health care distribution

(1)

Dental

5,737

61.5

5,466

58.9

271

5.0

Medical

2,991

32.1

3,274

35.3

(283)

(8.6)

Total health care distribution

8,728

93.6

8,740

94.2

(12)

(0.1)

Technology and value-added services

(2)

594

6.4

536

5.8

58

10.7

Total

9,322

100.0

9,276

100.0

46

0.5

The components of our sales growth were as follows:

Total Local

Currency

Growth

Foreign

Exchange

Impact

Total Sales

Growth

Local Currency Growth

Local Internal

Growth

Acquisition

Growth

Health care distribution

(1)

Dental Merchandise

1.7

4.0

5.7

(0.4)

5.3

Dental Equipment

2.7

1.5

4.2

(0.4)

3.8

Total Dental

1.9

3.5

5.4

(0.4)

5.0

Medical

(9.3)

0.7

(8.6)

(8.6)

Total Health Care Distribution

(2.3)

2.4

0.1

(0.2)

(0.1)

Technology and value-added services

(2)

7.2

3.8

11.0

(0.3)

10.7

Total

(1.7)

2.5

0.8

(0.3)

0.5

Note: Percentages for Net Sales; Gross Profit; Selling, General and Administrative; Other Expense, Net; and Income Taxes are based on

actual values and may not recalculate due to rounding.

(1)

Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and

generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic

products), diagnostic tests, infection-control products, PPE products and vitamins.

(2)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,

practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing

education services for practitioners, consulting and other services.

Global Sales

Global net sales for the nine months ended September 30, 2023 increased 0.5%. The components of our sales

growth are presented in the table above.

The estimated increase in internally generated local currency sales, excluding PPE products and COVID-19 test

kits, was 3.5%. We estimate that sales of PPE products and COVID-19 test kits were approximately $540 million

and $990 million for the nine months ended September 30, 2023 and September 24, 2022, respectively,

representing an estimated decrease of $450 million or 45.5% versus the prior year, with the $450 million net

decrease year-over-year representing 4.8% of global net sales for the nine months ended September 30, 2023.

Dental

Dental net sales for the nine months ended September 30, 2023 increased 5.0%. The components of our sales

growth are presented in the table above. Our sales growth in local currency for dental merchandise was primarily

attributable to acquisitions. Our sales growth in local currency for dental equipment was primarily attributable to

growth in traditional equipment sales in North America.

The estimated increase in internally generated local currency sales, excluding PPE products and COVID-19 test

kits, was 3.8%. We estimate that sales of PPE products were approximately $264 million and $351 million for the

nine months ended September 30, 2023 and September 24, 2022, respectively, representing an estimated decrease

of $87 million or 25.0% versus the prior year, with the $87 million net decrease year-over-year representing 1.5%

of dental net sales for the nine months ended September 30, 2023.

Medical

Medical net sales for the nine months ended September 30, 2023 decreased 8.6%. The components of this decrease

are presented in the table above. The local currency decrease in medical sales is primarily attributable to lower

sales of PPE products and COVID-19 test kits and other point-of-care diagnostic products.

The estimated increase in internally generated local currency sales, excluding PPE products and COVID-19 test

kits, was 2.3%. We estimate that sales of PPE products and COVID-19 test kits were approximately $276 million

and $639 million for the nine months ended September 30, 2023 and September 24, 2022, respectively,

representing an estimated decrease of $363 million or 56.8% versus the prior year, with the $363 million net

decrease year-over-year representing 12.1% of medical net sales for the nine months ended September 30, 2023.

Technology and value-added services

Technology and value-added services net sales for the nine months ended September 30, 2023 increased 10.7%.

The components of our sales growth are presented in the table above. During the nine months ended September 30,

2023, the trend for sales of practice management software growth remains strong as we continued to increase the

number of cloud-based users. We also experienced increased demand for our revenue cycle management solutions.

The increase in sales during the quarter ended September 30, 2023 was partially offset by the expiration, during the

third quarter of 2022, of a modestly profitable government contract in one of our value-added services businesses.

Gross Profit

Gross profit and gross margin percentages by segment and in total were as follows:

September 30,

Gross

September 24,

Gross

Increase

2023

Margin %

2022

Margin %

Health care distribution

2,534

29.0

2,482

28.4

52

2.1

Technology and value-added services

402

67.6

350

65.3

52

14.8

Total

2,936

31.5

2,832

30.5

104

3.7

As a result of different practices of categorizing costs associated with distribution networks throughout our

industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we

realize substantially higher gross margin percentages in our technology and value-added services segment than in

our health care distribution segment. These higher gross margins result from being both the developer and seller of

software products and services, as well as certain financial services. The software industry typically realizes higher

gross margins to recover investments in research and development.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in

the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting

our gross profit margin. For example, sales of our corporate brand products achieve gross profit margins that are

higher than average total gross profit margins of all products. With respect to customer mix, sales to our large-

group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the

gross margin on sales to office-based practitioners, who normally purchase lower volumes.

Health care distribution gross profit for the nine months ended September 30, 2023 increased compared to the

prior-year period due to the increase in sales, mainly due to a reduction in sales of PPE products and COVID-19 test kits offset by $74 million of gross profit from acquisitions and gross margin expansion as a result of a favorable impact of sales mix of higher-margin products.

Technology and value-added services gross profit increased as a result of a higher gross profit from internally

generated sales and gross profit of $18 million from acquisitions, as well as an increase in gross margin rates

primarily due to product mix and increases in productivity.

Operating Expenses

Operating expenses (consisting of selling, general and administrative expenses; depreciation and amortization; and

restructuring and integration costs) by segment and in total were as follows:

% of

% of

September 30,

Respective

September 24,

Respective

Increase

2023

Net Sales

2022

Net Sales

Health care distribution

2,063

23.6

1,903

21.8

160

8.4

Technology and value-added services

297

50.1

254

47.4

43

17.0

Total

2,360

25.3

2,157

23.3

203

9.4

The net increase in operating expenses is attributable to the following:

Restructuring and

Integration Costs

Operating Costs

Acquisitions

Total

Health care distribution

42

81

37

160

Technology and value-added services

7

4

32

43

Total

49

85

69

203

The restructuring and integration costs are primarily related to severance and employee-related costs, accelerated

amortization of right-of-use lease assets and fixed assets, and other lease exit costs. During the nine months ended

September 30, 2023, our operating expenses were favorably impacted by the recognition of a remeasurement gain

of $18 million following an acquisition of a controlling interest of a previously held equity investment. The

increase in operating costs includes increases in payroll and payroll related costs, travel, convention, consulting,

and occupancy expenses in both of our reportable segments and increased acquisition expenses in our healthcare

distribution segment.

Other Expense, Net

Other expense, net was as follows:

September 30,

September 24,

Variance

2023

2022

Interest income

12

5

7

132.2

Interest expense

(58)

(23)

(35)

(153.4)

Other, net

(2)

1

(3)

(331.4)

Other expense, net

(48)

(17)

(31)

(184.5)

Interest income increased primarily due to increased interest rates. Interest expense increased primarily due to

increased borrowings and increased interest rates.

Income Taxes

For the nine months ended September 30, 2023 our effective tax rate was 22.5% compared to 23.5% for the prior

year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state

and foreign income taxes and interest expense.

Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases of additional noncontrolling

interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and

repurchases of common stock. Working capital requirements generally result from increased sales, special

inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have

tended to be stronger during the second half of the year and special inventory forward buy-in opportunities have

been most prevalent just before the end of the year, and have caused our working capital requirements to be higher

from the end of the third quarter to the end of the first quarter of the following year.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt

placements. Please see

Note 8 – Debt

for further information. Our ability to generate sufficient cash flows from

operations is dependent on the continued demand of our customers for our products and services, and access to

products and services from our suppliers.

Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the

year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of

sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate

future increases in our working capital requirements.

We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on

forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change

our funding structure to reflect any new requirements.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,

and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently

foreseeable short-term and long-term capital needs.

Our acquisition strategy is focused on investments in companies that add new customers and sales teams, increase

our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we

have already invested in businesses), and finally, those that enable us to access new products and technologies. As

part of our BOLD+1 Strategic Plan, including pursuing focused mergers and acquisitions, subsequent to September

30, 2023 we have announced acquisitions of companies specializing in clear aligners, homecare medical products

delivered directly to patients, and dental practice transition services.

Net cash provided by operating activities was $532 million for the nine months ended September 30, 2023,

compared to net cash provided by operating activities of $348 million for the prior year. The net change of $184

million was primarily due to a favorable change in working capital (primarily inventories), net of acquisitions,

partially offset by a decrease in operating income.

Net cash used in investing activities was $808 million for the nine months ended September 30, 2023, compared to

net cash used in investing activities of $211 million for the prior year. The net change of $597 million was

primarily attributable to increased business combinations and investment activity.

Net cash provided by financing activities was $307 million for the nine months ended September 30, 2023,

compared to net cash used in financing activities of $121 million for the prior year. The net change of $428 million

was primarily due to increased net borrowings from debt.

The following table summarizes selected measures of liquidity and capital resources:

September 30,

December 31,

2023

2022

Cash and cash equivalents

166

117

Working capital

(1)

2,020

1,764

Debt:

Bank credit lines

12

103

Current maturities of long-term debt

72

6

Long-term debt

1,815

1,040

Total debt

1,899

1,149

Leases:

Current operating lease liabilities

74

73

Non-current operating lease liabilities

314

275

(1)

Includes $0 million and $327 million of certain accounts receivable which serve as security for U.S. trade accounts receivable

securitization at September 30, 2023 and December 31, 2022, respectively.

Our cash and cash equivalents consist of bank balances and investments in money market funds representing

overnight investments with a high degree of liquidity.

Accounts receivable days sales outstanding and inventory turns

Our accounts receivable days sales outstanding from operations increased to 43.7 days as of September 30, 2023

from 42.9 days as of September 24, 2022. During the nine months ended September 30, 2023, we wrote off

approximately $13 million of fully reserved accounts receivable against our trade receivable reserve. Our inventory

turns from operations decreased to 4.5 as of September 30, 2023 from 4.7 as of September 24, 2022. Our working

capital accounts may be impacted by current and future economic conditions.

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles,

and certain equipment. Our leases have remaining terms of one year to approximately 18 years, some of which

may include options to extend the leases for up to 15 years. As of September 30, 2023, our right-of-use assets

related to operating leases were $323 million and our current and non-current operating lease liabilities were $74

million and $314 million, respectively.

Stock Repurchases

On February 8, 2023, our Board of Directors authorized the repurchase of up to an additional $400 million in shares

of our common stock.

From March 3, 2003 through September 30, 2023, we repurchased $4.7 billion, or 89,702,364 shares, under our

common stock repurchase programs, with $315 million available as of September 30, 2023 for future common

stock share repurchases.

Critical Accounting Policies and Estimates

There have been no material changes in our critical accounting policies and estimates from those disclosed in Item

7 of our Annual Report on Form 10-K for the year ended December 31, 2022, except accounting policies adopted

as of January 1, 2023, which are discussed in

Note 2 - Critical Accounting Policies and Recently Issued Accounting

Standards

of the Notes to the Condensed Consolidated Financial Statements included under Item 1.

Accounting Standards Update

For a discussion of accounting standards updates that have been adopted or will be adopted, see

Note 2 - Critical

Accounting Policies and Recently Issued Accounting Standards

of the Notes to the Condensed Consolidated

Financial Statements included under Item 1.

Market risk

As filed, 170 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in our exposure to market risk from that disclosed in Item 7A of our Annual

Report on Form 10-K for the year ended December 31, 2022.

Controls and procedures

As filed, 4,736 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of management, including our principal executive officer and

principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and

procedures as of the end of the period covered by this quarterly report as such term is defined in Rules 13a-15(e)

and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based

on this evaluation, our management, including our principal executive officer and principal financial officer,

concluded that our disclosure controls and procedures were effective as of September 30, 2023, to ensure that all

material information required to be disclosed by us in reports that we file or submit under the Exchange Act is

accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and

that all such information is recorded, processed, summarized and reported within the time periods specified in the

SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2023, we acquired a 100% voting equity interest in S.I.N Implant System,

an implant manufacturer headquartered in Brazil. The full integration of this acquisition, as well as our previously

reported acquisition of Biotech Dental, will extend beyond year-end and, therefore, we anticipate excluding Biotech

Dental, and S.I.N. from our annual assessment of internal control over financial reporting as of December 30, 2023,

as permitted by SEC staff interpretive guidance for newly acquired businesses.

Post-acquisition integration related activities for other dental and medical businesses acquired during prior quarters

across the U.S., Europe, Australia, China, and Brazil will continue, and will be included in our annual assessment

of internal control over financial reporting as of December 30, 2023. These acquisitions, the majority of which

utilize separate information and financial accounting systems, have been included in our condensed consolidated

financial statements since their respective dates of acquisition.

Finally, we continued systems implementation activities in the U.S. for two of our dental businesses.

The combination of acquisitions (including S.I.N., and Biotech Dental), continued acquisition integrations and

systems implementation activities undertaken during the quarter and carried over from prior quarters when

considered in the aggregate, represents a material change in our internal control over financial reporting.

During the quarter, all acquisitions, continued acquisition integrations and systems implementation activities

involve necessary and appropriate change-management controls that are considered in our quarterly assessment of

changes in our internal control over financial reporting.

Subsequent to the September 30, 2023 quarter end, on October 14, 2023, we experienced a cybersecurity incident

that primarily affected the operations of our North American and European dental and medical distribution

businesses. As part of the Company’s incident response plan, precautionary actions were taken to contain the

incident including shutting down connectivity to networks and key business, operating and financial accounting

systems globally. In addition to notifying customers and all relevant law enforcement authorities, we engaged

external cyber-security experts to support our assessment of the cyber-incident’s impact as well as sanitize, rebuild

and restore our information systems.

On November 22, 2023, we experienced a disruption to our ecommerce platform and related applications. The

Company has restored its ecommerce platform and certain other applications in the United States, Canada and

certain European countries. Our ecommerce platform in the remaining European countries and other applications

are expected to follow shortly.

In order to mitigate the impact of this disruption on our systems and on our ability to service customers, alternative

procedures and controls were temporarily implemented. An investigation is ongoing to assess the impact on our

businesses and internal controls over financial reporting.

Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance

that the objectives of the internal control system are met. Because of the inherent limitations of any internal control

system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company

have been detected.

Risk factors

As filed, 2,506 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Referring to risk factors disclosed in Part 1, Item 1A, of our Annual Report on Form 10-K for the year ended

December 31, 2022, and in particular the first risk factor under General Risks addressing security risks associated

with our information systems, the third paragraph is amended and restated as follows:

While we have implemented measures to protect our IS systems, such measures may not prevent these events. Any

such security incidents could disrupt our operations, harm our reputation, or otherwise have a material adverse

effect on our business. In addition to immaterial prior incidents, in October 2023, Henry Schein experienced a

cybersecurity incident that primarily affected the operations of our North American and European dental and

medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management

and patient relationship management solutions business was not affected, and our manufacturing businesses and our

equipment sales and service operations were mostly unaffected. Once we became aware of the issue, we took steps

to assess, contain and remediate this incident.

We

restored affected systems and applications, our distribution

operations resumed and we reactivated our ecommerce platform.

We

also notified law enforcement and our

customers and suppliers, informing them of both the incident and management’s efforts to mitigate its impact on

our daily operations. As previously disclosed, while our forensic investigation is still ongoing, we have determined

that a data breach occurred. We are notifying potentially affected parties as appropriate. On November 22, 2023,

we experienced a disruption to our ecommerce platform and related applications. The Company has restored its

ecommerce platform and certain other applications in the United States, Canada and certain European

countries. Our ecommerce platform in the remaining European countries and other applications are expected to

follow shortly.

We

continue to review the impact of the incident on the Company’s business. As previously

disclosed, we believe the incident will adversely impact our financial results for the fourth quarter and full year

2023. We maintain cyber insurance, subject to certain retentions and policy limitations. There can be no assurance

that the insurance coverage we maintain is sufficient or will be available in adequate amounts or at a reasonable

cost to cover costs and expenses related to security incidents.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-07-02 to 2023-09-30$3.16bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2023-01-01 to 2023-09-30$9.32bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-07-02 to 2023-09-30$2.17bnus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2023-01-01 to 2023-09-30$6.39bnus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-07-02 to 2023-09-30$995.0mus-gaap:GrossProfit
Gross profit9 months2023-01-01 to 2023-09-30$2.94bnus-gaap:GrossProfit
Selling, general and administrative3 months2023-07-02 to 2023-09-30$725.0mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2023-01-01 to 2023-09-30$2.15bnus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-07-02 to 2023-09-30$200.0mus-gaap:OperatingIncomeLoss
Operating income9 months2023-01-01 to 2023-09-30$576.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-07-02 to 2023-09-30$25.0mus-gaap:InterestExpense
Interest expense9 months2023-01-01 to 2023-09-30$58.0mus-gaap:InterestExpense
Income tax3 months2023-07-02 to 2023-09-30$39.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2023-01-01 to 2023-09-30$119.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-02 to 2023-09-30$137.0mus-gaap:NetIncomeLoss
Net income9 months2023-01-01 to 2023-09-30$398.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-02 to 2023-09-30$1.05us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2023-01-01 to 2023-09-30$3.02us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-02 to 2023-09-30$1.06us-gaap:EarningsPerShareBasic
Basic EPS9 months2023-01-01 to 2023-09-30$3.04us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-02 to 2023-09-30131,442,135 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2023-01-01 to 2023-09-30132,149,172 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2023-01-01 to 2023-09-30$532.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2023-01-01 to 2023-09-30$108.0mus-gaap:PaymentsToAcquireProductiveAssets
Share repurchases9 months2023-01-01 to 2023-09-30$200.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Current assetsAt period end2023-09-30$4.11bnus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$9.81bnus-gaap:Assets
Current liabilitiesAt period end2023-09-30$2.09bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$4.71bnus-gaap:Liabilities
Short-term borrowingsAt period end2023-09-30$12.0mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2023-09-30$3.65bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001000228-23-000052. Last ingested by Listed: Nov 12, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.